Comparison · NCT04960202-2ca8d32f
PF-07321332 300 mg + Ritonavir 100 mg vs Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PF-07321332 300 mg + Ritonavir 100 mg vs Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs). Trial comparisons, record NCT04960202-2ca8d32f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04960202-2ca8d32f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.22 | 0.196 | 0.246 | wilson | |
| Risk in group 2 | 0.243 | 0.218 | 0.27 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0235 | -0.0595 | 0.0127 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.903 | 0.773 | 1.06 | log | |
| Odds ratio, group 1 over group 2 | 0.876 | 0.715 | 1.07 | log | |
| Number needed to treat, for one fewer participant with the outcome on PF-07321332 300 mg + Ritonavir 100 mg than on Placebo | 42.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PF-07321332 300 mg + Ritonavir 100 mg | Participants with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received 300 milligrams (mg) PF-07321332 coadministered with 100 mg ritonavir orally, q12h for 5 days. Participants were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24. | 228 | 1,038 | OG000 |
| Group 2 | Placebo | Participants with SARS-CoV-2 infection received placebo orally, q12h for 5 days. Participants were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24. | 256 | 1,053 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)
- Description
An adverse event (AE) was any untoward medical occurrence in a participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. Serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect; a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical events. AEs included both SAEs and all non-SAEs. An AE was considered as TEAE if the event started on or after start date of study intervention.
- Time frame
- From start of study intervention (Day 1) up to end of safety follow-up (Day 34)
- Population
- Safety analysis set (SAS) included all participants who received at least one dose of study intervention.
Source ClinicalTrials.gov
Trial
- Title
- EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
- NCT number
- NCT04960202
- Phases
- PHASE2, PHASE3
- Conditions
- COVID-19
- Interventions
- PF-07321332, Ritonavir, Placebo
- Lead sponsor
- Pfizer
- Results first posted
- 2023-02-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04960202?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04960202-2ca8d32f